The aim of the study was to evaluate the effect of light-moderate aerobic exercise on BMD in postmenopausal osteopenic women using bone formation-resorption markers. Participants were randomized into two groups as aerobic exercise and control groups and followed for 12 weeks. At the beginning and at the 12th week, bone formation-resorption markers including procollagen type 1 N-terminal propeptide (P1NP), cross-linked C-telopeptide of type 1 collagen (CTX), osteocalcin, malondialdehyde, non-bone-specific total alkaline phosphatase, 25(OH)D3 and oxidative markers such as parathyroid hormone (PTH) were evaluated in serum and whether there was a difference between the 2 groups.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The serum levef of Procollagen type 1 N-terminal propeptide (P1NP) (ng/ml)
Timeframe: From enrollment to the end of treatment at 12 weeks
The serum levef of Cross-linked C-telopeptide of type I collagen (CTX) (ng/ml)
Timeframe: From enrollment to the end of treatment at 12 weeks
The serum levef of Osteocalcin(OCN) (ng/ml)
Timeframe: From enrollment to the end of treatment at 12 weeks
The serum levef of nonbone-specific total alkaline phosphatase (ALP) (U/L)
Timeframe: From enrollment to the end of treatment at 12 weeks